Patidegib

N/A

Report date: 2023/12/11 17:37:40
NME

Base Information

Drug NamePatidegib
Drug Alias NamePatidegib-hydrochloride帕替地吉盐酸盐帕替德吉盐酸盐SaridegibSaridegib hydrochloride +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSmoothened receptor antagonists
TargetsSmoothened receptor
Therapy Area/IndicationsPrimary MyelofibrosisHead and Neck NeoplasmsPancreatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesInfinity Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSol-Gel Technologies Ltd
Inactive CompaniesInfinity Pharmaceuticals IncPellepharm IncUniversity Of Colorado Denver
Active IndicationsBasal Cell Nevus Syndrome
Inactive IndicationsPrimary MyelofibrosisHead and Neck NeoplasmsPancreatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A